Search results for "Insulin"

showing 10 items of 1360 documents

Antioxidant supplements in exercise: worse than useless?

2012

TO THE EDITOR: In a recent paper by Higashida et al. (5), the authors report that very large doses of antioxidant vitamins do not prevent the exercise-induced adaptive responses of muscle mitochondria, GLUT4, and insulin action to exercise. As clearly stated in the paper, their data disagree with those reported by three independent research groups from Germany (14), Australia (17), and Spain (4). Using a significantly different experimental protocol regarding exercise training intensity and duration, antioxidant supplementation (doses and types of antioxidants), and molecular parameters analyzed (mRNA vs. protein levels), Higashida et al. compared their data with ours and came to exactly th…

medicine.medical_specialtyAntioxidantVitamin CbiologyPhysiologybusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulinSkeletal muscleClinical nutritionmedicine.anatomical_structureEndocrinologyMitochondrial biogenesisPhysiology (medical)Internal medicinemedicinebiology.proteinbusinessInhibitory effectGLUT4American Journal of Physiology-Endocrinology and Metabolism
researchProduct

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

2011

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other…

medicine.medical_specialtyAntioxidantmedicine.medical_treatmentHyperlipidemiasDiseaseBioinformaticsmetabolic syndromeAntioxidants03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseWeight lossinsulin resistanceDiabetes mellitusInternal medicineDrug Discoverymedicineoxidative stressHumansObesityEndothelial dysfunctionantioxidants cardiovascular disease insulin resistance metabolic syndrome oxidative stress reactive oxygen species.Dyslipidemias030304 developmental biologyreactive oxygen speciesInflammationMetabolic SyndromePharmacology0303 health sciencesbusiness.industryThrombosismedicine.disease3. Good healthFatty LiverClinical trialOxidative StressantioxidantsEndocrinologyObesity Abdominal030220 oncology & carcinogenesisHypertensionInsulin ResistanceMetabolic syndromemedicine.symptombusinessSignal TransductionCurrent Pharmaceutical Design
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

The Influence of Treated and Untreated Subclinical Hypothyroidism on Metabolic Profile in Women with Polycystic Ovary Syndrome.

2021

Background. Polycystic ovary syndrome (PCOS) and hypothyroidism are the most common endocrinological disorders among women of reproductive age. Since hypothyroidism occurs more frequently in PCOS patients, it is vital to explain its clinical impact. Aim. To evaluate the impact of subclinical hypothyroidism (SCH) and its treatment on the metabolic profile of patients with PCOS. Methods. 190 women with PCOS phenotype A were enrolled in the case-control study. They were divided into three groups: 38 women with PCOS and subclinical hypothyroidism, 76 women with PCOS and SCH under thyroid replacement therapy, and 76 women with PCOS and normal thyroid function (control group). Serum lipids, fasti…

medicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBlood lipidsDiseases of the endocrine glands. Clinical endocrinologychemistry.chemical_compoundEndocrinologyInsulin resistanceInternal medicineMedicineSubclinical infectionEndocrine and Autonomic Systemsbusiness.industryCholesterolInsulinThyroidnutritional and metabolic diseasesRC648-665medicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structurechemistryThyroid functionbusinessResearch ArticleInternational journal of endocrinology
researchProduct

Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?

2011

Clinical evidence and the recent decisions of the European Medicines Agency and the Food and Drug Administration challenge the safety of thiazolidinediones treatment. Recently, this treatment has been suggested for Friedreich's ataxia because thiazolidinediones improve neurological symptoms. Hypertrophic cardiomyopathy is the most prevalent cardiac feature and the cause of premature death in Friedreich's ataxia patients. We recommend that therapy with peroxisome proliferator-activated receptor-gamma agonists like thiazolidinediones be taken with caution, as they cause a decrease in the number of fast fibers and an increase in mitochondrial biogenesis in cardiac muscle because of the inducti…

medicine.medical_specialtyAtaxiaHeart diseasebusiness.industryInsulinmedicine.medical_treatmentHypertrophic cardiomyopathymedicine.diseaseBioinformaticsEndocrinologyNeurologyMitochondrial biogenesisHeart failureInternal medicinemedicineNeurology (clinical)medicine.symptomRosiglitazonebusinessPioglitazonemedicine.drugMovement Disorders
researchProduct

Management of Dyslipidemia in the Metabolic Syndrome

2007

In order to characterize the metabolic syndrome it becomes necessary to establish a number of diagnostic criteria. Because of its impact on cardiovascular morbidity/mortality, considerable attention has been focussed on the dyslipidemia accompanying the metabolic syndrome. The aim of this review is to highlight the fundamental aspects of the pathophysiology, diagnosis, and the treatment of the metabolic syndrome dyslipidemia with recommendations to clinicians. The clinical expression of the metabolic syndrome dyslipidemia is characterized by hypertriglyceridemia and low levels of high-density lipoprotein-cholesterol (HDL-C). In addition, metabolic syndrome dyslipidemia is associated with hi…

medicine.medical_specialtyBioinformaticsClofibric Acidchemistry.chemical_compoundInsulin resistanceInternal medicineHyperlipidemiamedicineHumansPharmacology (medical)DyslipidemiasMetabolic Syndromemedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseEndocrinologyPostprandialchemistrySpainPractice Guidelines as Topiclipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic syndromeCardiology and Cardiovascular MedicineLipid profilebusinessDyslipidemiaAmerican Journal of Cardiovascular Drugs
researchProduct

In vitro reprogramming of pancreatic alpha cells towards a beta cell phenotype following ectopic HNF4α expression

2015

There is currently a shortage of organ donors available for pancreatic beta cell transplantation into diabetic patients. An alternative source of beta cells is pre-existing pancreatic cells. While we know that beta cells can arise directly from alpha cells during pancreatic regeneration we do not understand the molecular basis for the switch in phenotype. The aim of the present study was to investigate if hepatocyte nuclear factor 4 alpha (HNF4α), a transcription factor essential for a normal beta cell phenotype, could induce the reprogramming of alpha cells towards potential beta cells. We utilised an in vitro model of pancreatic alpha cells, the murine αTC1-9 cell line. We initially chara…

medicine.medical_specialtyBiologyBiochemistryAlpha cellCell LineMiceEndocrinologyInsulin-Secreting CellsInternal medicinemedicineAnimalspancreatic alpha cellsMolecular Biologyreprogramming3T3-L1Cellular ReprogrammingAntigens Differentiationbeta cellCell biologyEndocrinologyHepatocyte Nuclear Factor 4Glucagon-Secreting CellsCell cultureHepatocyte nuclear factor 4 alphaPAX4Ectopic expressionBeta cellReprogrammingMolecular and Cellular Endocrinology
researchProduct

Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bip…

2022

OBJECTIVES Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and C-Reactive Protein (CRP) are markers of inflammation that are elevated in bipolar disorder (BD) and are also related to a higher risk of metabolic syndrome (MetS). This study aimed at investigating for the first time the association between NLR, PLR, and CRP and the metabolic status in BD. METHODS We assessed the association between biomarkers and the metabolic status: number of metabolic risk factors, presence of MetS, insulin sensitivity (Quantitative Insulin Sensitivity Check Index, QUICKI) and insulin resistance (Homeostatic Model Assessment for Insulin Resistance, HOMA-IR index), in a sample of 219 outpa…

medicine.medical_specialtyBipolar DisorderNeutrophilsLymphocyteInflammationGastroenterologyInsulin resistanceInternal medicinemedicineHumansLymphocytesBipolar disorderBiological PsychiatryRetrospective StudiesMetabolic SyndromebiologyPlatelet Countbusiness.industryC-reactive proteinQuantitative insulin sensitivity check indexmedicine.diseasePsychiatry and Mental healthC-Reactive Proteinmedicine.anatomical_structurebiology.proteinHomeostatic model assessmentInsulin ResistanceMetabolic syndromemedicine.symptombusinessBiomarkersThe World Journal of Biological Psychiatry
researchProduct

Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I

2000

This study was conducted to evaluate the influence of proinsulin C-peptide on erythrocyte Na(+),K(+)-ATPase and endothelial nitric oxide synthase activities in patients with type I diabetes. In a randomized double-blind study design, ten patients with type I diabetes received intravenous infusions of either human C-peptide or physiological saline on two different occasions. C-peptide was infused at a rate of 3 pmol.min(-1).kg(-1) for 60 min, and thereafter at 10 pmol.min(-1).kg(-1) for 60 min. At baseline and after 60 and 120 min, laser Doppler flow (LDF) was measured following acetylcholine iontophoresis or mild thermal stimulation (44 degrees C), and venous blood samples were collected to…

medicine.medical_specialtyC-peptideArbitrary unitNitric Oxide Synthase Type IIIVenous bloodGeneral MedicineNitric oxidechemistry.chemical_compoundRed blood cellEndocrinologymedicine.anatomical_structurechemistryInternal medicinemedicineAcetylcholinemedicine.drugProinsulinClinical Science
researchProduct

Activation of adipose tissue cannabinoid receptors 1 (CB1R) alters antilipolytic action of insulin and increases lipolysis in mice

2014

medicine.medical_specialtyCannabinoid receptorEndocrinologyChemistryInternal medicineInsulinmedicine.medical_treatmentmedicineLipolysisAdipose tissueCardiology and Cardiovascular MedicineAtherosclerosis
researchProduct